TY - JOUR
T1 - Estimated cognitive decline in patients with schizophrenia
T2 - A multicenter study
AU - for COCORO
AU - Fujino, Haruo
AU - Sumiyoshi, Chika
AU - Yasuda, Yuka
AU - Yamamori, Hidenaga
AU - Fujimoto, Michiko
AU - Fukunaga, Masaki
AU - Miura, Kenichiro
AU - Takebayashi, Yuto
AU - Okada, Naohiro
AU - Isomura, Shuichi
AU - Kawano, Naoko
AU - Toyomaki, Atsuhito
AU - Kuga, Hironori
AU - Isobe, Masanori
AU - Oya, Kazuto
AU - Okahisa, Yuko
AU - Takaki, Manabu
AU - Hashimoto, Naoki
AU - Kato, Masaki
AU - Onitsuka, Toshiaki
AU - Ueno, Takefumi
AU - Ohnuma, Tohru
AU - Kasai, Kiyoto
AU - Ozaki, Norio
AU - Sumiyoshi, Tomiki
AU - Imura, Osamu
AU - Hashimoto, Ryota
N1 - Funding Information:
We thank all of the individuals who participated in this study. This work was supported by a Grant-in-Aid for Scientific Research (B) (25293250, 16H05375), a Grant-in-Aid for Young Scientists (B) (26860924), and a Grant-in-Aid for Scientific Research on Innovative Areas (16H01689, 16H06395, 16H06399, 16K21720) from the Japan Society for the Promotion of Science, Brain/MINDS by AMED, and the Program for Creating Future Wisdom at Osaka University. The funders had no role in the study design, data collection and analyses, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2016 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology
PY - 2017/5
Y1 - 2017/5
N2 - Aim: Studies have reported that cognitive decline occurs after the onset of schizophrenia despite heterogeneity in cognitive function among patients. The aim of this study was to investigate the degree of estimated cognitive decline in patients with schizophrenia by comparing estimated premorbid intellectual functioning and current intellectual functioning. Methods: A total of 446 patients with schizophrenia (228 male, 218 female), consisting of three sample sets obtained from 11 psychiatric facilities, and 686 healthy controls participated in this study. The Wechsler Adult Intelligence Scale-III (WAIS-III) was used to measure the participants’ current full-scale IQ (FSIQ). The premorbid IQ was estimated using the Japanese Adult Reading Test-25. Estimated cognitive decline (difference score) was defined as the difference between the estimated premorbid IQ and the current FSIQ. Results: Patients with schizophrenia showed greater estimated cognitive decline, a lower FSIQ, and a lower premorbid IQ compared with the healthy controls. The mean difference score, FSIQ, and estimated premorbid IQ were −16.3, 84.2, and 100.5, respectively, in patients with schizophrenia. Furthermore, 39.7% of the patients had a difference score of 20 points or greater decline. A discriminant analysis showed that the difference score accurately predicted 81.6% of the patients and healthy controls. Conclusion: These results show the distribution of difference score in patients with schizophrenia. These findings may contribute to assessing the severity of estimated cognitive decline and identifying patients with schizophrenia who suffer from cognitive decline.
AB - Aim: Studies have reported that cognitive decline occurs after the onset of schizophrenia despite heterogeneity in cognitive function among patients. The aim of this study was to investigate the degree of estimated cognitive decline in patients with schizophrenia by comparing estimated premorbid intellectual functioning and current intellectual functioning. Methods: A total of 446 patients with schizophrenia (228 male, 218 female), consisting of three sample sets obtained from 11 psychiatric facilities, and 686 healthy controls participated in this study. The Wechsler Adult Intelligence Scale-III (WAIS-III) was used to measure the participants’ current full-scale IQ (FSIQ). The premorbid IQ was estimated using the Japanese Adult Reading Test-25. Estimated cognitive decline (difference score) was defined as the difference between the estimated premorbid IQ and the current FSIQ. Results: Patients with schizophrenia showed greater estimated cognitive decline, a lower FSIQ, and a lower premorbid IQ compared with the healthy controls. The mean difference score, FSIQ, and estimated premorbid IQ were −16.3, 84.2, and 100.5, respectively, in patients with schizophrenia. Furthermore, 39.7% of the patients had a difference score of 20 points or greater decline. A discriminant analysis showed that the difference score accurately predicted 81.6% of the patients and healthy controls. Conclusion: These results show the distribution of difference score in patients with schizophrenia. These findings may contribute to assessing the severity of estimated cognitive decline and identifying patients with schizophrenia who suffer from cognitive decline.
UR - http://www.scopus.com/inward/record.url?scp=85006951938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006951938&partnerID=8YFLogxK
U2 - 10.1111/pcn.12474
DO - 10.1111/pcn.12474
M3 - Article
C2 - 27804186
AN - SCOPUS:85006951938
SN - 1323-1316
VL - 71
SP - 294
EP - 300
JO - Psychiatry and clinical neurosciences
JF - Psychiatry and clinical neurosciences
IS - 5
ER -